Biosimilar Dispensing: A Potential Public Policy Problem

We may begin to see more movement on biosimilars in the marketplace now that FDA has finalized guidance documents following a 3-year delay. Still, many suggest it could take another year.

So, why have pharmaceutical companies started pushing for biosimilarity bills at the state level? Without any products in the marketplace and no identified problems, you have to wonder what is behind their push.

I hope the pharmacy industry doesn’t have to engage in another state-by-state effort to allow the dispensing of appropriate biosimilar products. This will be an interesting public policy issue to follow over the next few years.